Building on a pact from 2022, Eli Lilly has signed a new discovery collaboration with Abbisko Therapeutics that could see it pay the Chinese biotech up to $1.9 billion.
Building on a pact from 2022, Eli Lilly has signed a new discovery collaboration with Abbisko Therapeutics that could see it pay the Chinese biotech …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Eli Lilly, Abbisko Expand Drug Hunt With $1.9 Billion Research Pact - Eli Lilly (NYSE:LLY)
Abbisko Teams Up With Lilly In Latest U.S.-China Pharma Collaboration
Abbisko Therapeutics Deepens R&D Collaboration with Lilly
AbbVie's Big Immunology Acquisition
BioArctic and Lilly sign research and collaboration agreement combining Lilly compound with BioArctic's BrainTransporter™ technology
AbbVie’s Costly Apogee Acquisition Has Long-Term Upside: Analyst - AbbVie (NYSE:ABBV), Apogee Therapeutic
AI drug discovery firm Insilico Medicine signs deal with Korea’s SK Biopharmaceuticals worth $2.5 billion | Fortune
Abbisko Therapeutics signed a new Eli Lilly partnership worth up to $1.9 billion to develop novel medicines globally.
Strategic research collaboration and license agreement is worth up to $1.9 billion to Abbisko
Abbisko Therapeutics Deepens R&D Collaboration with Lilly
Worth as much as $1.9 billion, the deal directs Ascidian to help Lilly find potential drugs for genetically driven kidney…
U.S. pharmaceutical giant Eli Lilly will give Hong Kong-listed Insilico $115 million upfront to bring some of its AI-discovered…
Eli Lilly has invested in Abridge as the health tech startup expands into clinical trial recruitment and broadens its reach into…
